Redefining Philanthropic Drug Discovery

Explore the innovative approaches nonprofits are taking to bridge the gap between academic discoveries and successful drug development in this 58-minute panel discussion. Learn about the challenges in translating lab research to patient treatments, including resource limitations and high failure rates. Discover how nonprofit organizations are uniquely positioned to tackle high-risk projects through mission-driven approaches. Gain insights from industry experts on topics such as investment needs, government constraints, the role of disease-specific nonprofits, and various business models. Understand the impact of philanthropy on fundraising and the importance of impact investing in the drug development ecosystem. Hear from leaders in healthcare, venture funding, and research foundations as they discuss strategies for redefining philanthropic drug discovery and ensuring no opportunity is missed in bringing life-saving treatments to patients.

Introduction
Where is the need for investment
Twosided coin
Two different models
Why is philanthropy needed
The US government is constrained
The role of the smaller diseasebased nonprofits
Bright Edges mission
Monetization
Neuroscience
Compass Study
Unique Role
Business Models
The Challenge
The Infrastructure
HBS
MDA
Scientific Advisory Board
Difference between nonprofit and LLC model
Impact of philanthropy on fundraising
Impact investing
Ecosystem
Be a convener